Roche snags another Perjeta combo nod, but will 'weak' data limit its use?

Perjeta
Roche's Perjeta racked up $1.08 billion in sales through the first half of 2017.

Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped.

The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.

RELATED: How much does Perjeta add to Herceptin postsurgery? Depends how you slice it

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

Regulators based the go-ahead on data from a phase 3 trial that in June sent shares plunging and Roche scrambling for “damage control,” as one analyst put it. The reason? After a previous top-line announcement cued high hopes from industry watchers, the Swiss drugmaker revealed that adding Perjeta to the equation held off cancer in 94.1% of patients at the three-year markjust one percentage point more than the 93.2% of patients who achieved the same result on Herceptin and chemo alone.

Roche, for its part, pointed out that the difference translates to a 19% lower chance of developing invasive breast cancer. “The goal of treating breast cancer early is to provide people with the best chance for a cure. While we come closer to this goal with each advance, many people still have a recurrence and progress to the metastatic stage,” Roche CMO Sandra Horning said in a statement on the approval.

RELATED: ASCO fallout: Roche does 'damage control' after Perjeta combo disappoints investors

In June, though, Bernstein’s Tim Anderson called the data “weak” and predicted that they “very likely will confine use to higher-risk" patients, rather than the broader population.

Meanwhile, Rocheand Perjeta, specificallygot another regulatory boost alongside the post-surgery approval, with the FDA converting an accelerated approval for Perjeta-Herceptin-chemo trio in pre-surgery patients to a full approval. Pre-surgery use helped the medication rack up CHF 1.07 billion ($1.08 billion) in the first half of 2017 and push sales for Roche’s HER2 franchise up by 6% over the year-ago period.

Suggested Articles

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Gilead CEO John Milligan racked up $26M in 2018 pay, on paper at least, while incoming chief Daniel O'Day is in line for a cool $30M this year.

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.